 |
32 Diseases |  |
9 Trials |
|
9 Trials |  |
795 News |  |
| «12345678910111213» |
- Utilization of newly approved targeted immunomodulating treatments for atopic dermatitis (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_2274;
Initiators of tralokinumab, abrocitinib and upadacitinib had greater prior use of topical ruxolitinib and other treatments. Black race and Medicaid insurance were less likely to get newer treatments.
- Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca, Dupixent (dupilumab) / Sanofi, Regeneron
Association of countries (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_2272;
Dupilumab and tralokinumab utilization is greater in high-SDI countries than in lower-SDI countries, independent of atopic dermatitis burden. While biologic utilization is increasing globally, there are ongoing challenges in achieving equitable access to biologic therapies across diverse socioeconomic settings.
- Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Tralokinumab for the treatment of atopic dermatitis in adolescents, a multicenter, real-world study (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_2266;
Tralokinumab was well-tolerated and effective in treating adolescents with AD regardless of age, sex, AD phenotype, or ethnicity. This positive response aligns with clinical trial results, affirming tralokinumab as a valuable therapeutic option for moderate-to-severe AD.
- Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Tralokinumab formulated as a pre-filled pen was efficacious and well-tolerated in adults and adolescents with moderate-to-severe atopic dermatitis (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_2258;
P3
Both adult and adolescent patients were able to self-administer tralokinumab successfully with the pre-filled pen. There were no new AEs compared with the pivotal trials in adults and adolescents.
- Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Superresponders to tralokinumab in moderate-to-severe atopic dermatitis: a real-world multicentre study (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_2232;
At this time, no predictive factors for a rapid response have been established. The findings of this study indicate that a subset of patients exhibit a positive and rapid response to tralokinumab, which is sustained over time.
- Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Effect of Tralokinumab on Skin Barrier Function in Atopic Dermatitis (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_2228;
The findings of this study indicate that a subset of patients exhibit a positive and rapid response to tralokinumab, which is sustained over time. Tralokinumab demonstrates a promising effect on improving skin barrier function in patients with AD, showcasing significant improvements across various parameters such as TEWL, erythema, SCH, and skin temperature after 24 weeks of treatment.
- Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Effect of Tralokinumab on Skin Barrier Function in Atopic Dermatitis (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_2227;
Tralokinumab demonstrates a promising effect on improving skin barrier function in patients with AD, showcasing significant improvements across various parameters such as TEWL, erythema, SCH, and skin temperature after 24 weeks of treatment. Tralokinumab demonstrates a promising effect on improving skin barrier function in patients with AD, showcasing significant improvements across various parameters such as TEWL, erythema, SCH, and skin temperature after 24 weeks of treatment.
- Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca, Dupixent (dupilumab) / Sanofi, Regeneron
Real life data on the evolution of dupilumab-associated conjunctivitis in patients with atopic dermatitis after discontinuation of dupilumab and switching to tralokinumab or Janus kinase inhibitors (RESO-ADOC study) (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_2216;
Although uncommon, cunjunctivis can occur with dupilumab. In these cases, and in the absence of improvement, our study seems to suggest that a rapid switch to another molecule, particularly a JAKi, should be quickly considered for complete and rapid resolution of these ocular issues.
- Real-world data on epidemiological baseline characteristics of atopic dermatitis patients initiating advanced therapies. Comparative analysis of biologic drugs and small molecules in a single-centre study (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_2188;
It also pointed to distinct profiles of AD patients treated with biologics versus JAK inhibitors in our area. This could correlate with the physician choice of therapeutic alternative, considering their different mechanism of action.
- Treatment in real practice in Spain: efficacy and safety results from a 24-week multicenter study (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_2181;
The included patients significantly improved the signs and symptoms of AD, measured by EASI, SCORAD and pruritus VAS, as well as QoL, despite initial severity and refractoriness to multiple previous treatments. ensayo.
- Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Real-world clinical review of Tralokinumab in a tertiary centre (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_2179;
Tralokinumab offers an alternative for patients failing dupilumab due to conjunctivitis. Longer term follow up is needed to fully evaluate the real-world efficacy and tolerability of this promising therapy.
- Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Long-term safety and efficacy of tralokinumab in patients 65 years or older with moderate-to-severe atopic dermatitis (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_2169;
P2, P3
Longer term follow up is needed to fully evaluate the real-world efficacy and tolerability of this promising therapy. This pooled interim analysis suggests that long-term use of tralokinumab
- Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
A Case of Old Age Resistant Long-Standing Severe Atopic Dermatitis Complicated with Multiple Comorbidities Effectively and Safely Treated with Tralokinumab (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_2155;
In conclusion, the clinical evidence supports the use of tralokinumab as an effective therapeutic option for patients with moderate-to-severe AD. The safety of Tralokinumab has been established in patient groups with multiple comorbidities or receiving multiple medications.
- Dupixent (dupilumab) / Sanofi, Regeneron
Redness Face... Not just because of dupilumab (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_1782;
The safety of Tralokinumab has been established in patient groups with multiple comorbidities or receiving multiple medications. One of them discontinued treatment with jak inhibitor and switched to tralokinumab...Baricitinib, upadacitinib and abrocitinib are the i-JAKs indicated for atopic dermatitis, and although the development of acne is not uncommon both in the technical data sheet and in clinical practice, the development of
- ||||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Trial completion, Trial completion date: Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND (clinicaltrials.gov) - Aug 5, 2024
P3, N=1672, Completed, Sponsor: LEO Pharma
One of them discontinued treatment with jak inhibitor and switched to tralokinumab...Baricitinib, upadacitinib and abrocitinib are the i-JAKs indicated for atopic dermatitis, and although the development of acne is not uncommon both in the technical data sheet and in clinical practice, the development of Active, not recruiting --> Completed | Trial completion date: Jun 2025 --> Jul 2024
- | Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca, Dupixent (dupilumab) / Sanofi, Regeneron
Journal: Atopic dermatitis: real-life experience with tralokinumab after dupilumab failure: a case series. (Pubmed Central) - Aug 4, 2024
Active, not recruiting --> Completed | Trial completion date: Jun 2025 --> Jul 2024 No abstract available
- || Review, Journal: Severe atopic dermatitis in childhood in the era of personalized medicine (Pubmed Central) - Aug 2, 2024
We concluded that the high cost of these treatments often limits their prescription to situations where cases of atopic dermatitis are resistant to other conventional therapeutic options or when the disease reaches a severe degree. This underscores the importance of careful and accurate decision-making in the medical management of AD to ensure the efficient use of these therapeutic resources.
- | Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca, Dupixent (dupilumab) / Sanofi, Regeneron
Observational data, Journal: An Open-Label Prospective Observational Study of Tralokinumab in Atopic Dermatitis Patients with Inadequate Response to Dupilumab. (Pubmed Central) - Aug 1, 2024
This underscores the importance of careful and accurate decision-making in the medical management of AD to ensure the efficient use of these therapeutic resources. No abstract available
- ||| P3 data, Review, Journal: A Comprehensive Review of Biologics in Phase III and IV Clinical Trials for Atopic Dermatitis. (Pubmed Central) - Jul 27, 2024
The safety and efficacy of these biologics are comprehensively addressed in this review. This comprehensive review aims to explore the current landscape of biologic therapies for AD, delving into the latest research findings, clinical trial outcomes, and the diverse mechanisms of action employed by these novel interventions.
- || Review, Journal: Blocking the IL-4/IL-13 Axis versus the JAK/STAT Pathway in Atopic Dermatitis: How Can We Choose? (Pubmed Central) - Jul 27, 2024
Indeed, several important factors must be taken into account, such as the heterogeneity of AD and its classification in phenotypes, patients' comorbidities, age, and personal preferences. The aim of our review is to provide an overview of the clinical and molecular heterogeneities of AD and to explore the factors and parameters that, in clinical practice, may help inform clinical decision-making.
- | Rinvoq (upadacitinib) / AbbVie
Journal: Response to upadacitinib in a patient with atopic dermatitis and HIV. (Pubmed Central) - Jul 20, 2024
The aim of our review is to provide an overview of the clinical and molecular heterogeneities of AD and to explore the factors and parameters that, in clinical practice, may help inform clinical decision-making. No abstract available
- || Retrospective data, Review, Journal: Systematic review and network meta-analysis of the risk of malignancy with biologic therapies and selective Janus kinase-1 inhibitors in atopic dermatitis. (Pubmed Central) - Jul 19, 2024
Our analysis revealed no statistically significant increased risk of malignancy and no significant difference in the incidence of malignancy between selective JAK-1 inhibitors and dupilumab for the treatment of AD up to an average follow-up of 41 weeks. Nevertheless, further prospective studies with longer follow-up periods are warranted to confirm the safety of these therapies and their impact on the risk of malignancy.
- PATIENTS WITH SEVERE ATOPIC DERMATITIS CANDIDATES TO BIOLOGICAL THERAPY SHOW AN INCREASED PREVALENCE OF DYSPHAGIA: IMPLICATIONS FOR DIAGNOSIS AND MANAGEMENT OF COMORBID ATOPIC DISORDERS (Science Lounge) - Jul 18, 2024 - Abstract #UEGW2024UEGW_1097;
However, we found a higher likelihood of complaining of dysphagia in the subset of patients who were candidate to treatment with Dupilumab. Due to the reported augmented risk for atopic patients to develop EoE, screening AD patients complaining of dysphagia before initiating biologic treatment is pivotal to prevent EoE under-diagnosis and under-treatment.
- Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca, Dupixent (dupilumab) / Sanofi, Regeneron
Switching from Dupilumab to JAK inhibitors or Tralokinumab in case of facial or ocular adverse events: a real-life experience (Room 7.2) - Jul 8, 2024 - Abstract #EADV2024EADV_78;
- | Journal: Biologics and small molecules treatment for moderate-to-severe atopic dermatitis patients with comorbid conditions and special populations: an Italian perspective. (Pubmed Central) - Jul 3, 2024
Dupilumab, a groundbreaking biologic, gained approval as a significant milestone...Tralokinumab, a more recent approval, shows promise in clinical trials, particularly among younger populations...Janus Kinases inhibitors like Upadacitinib, Baricitinib, and Abrocitinib hold substantial potential for AD treatment...While these therapies offer promise, especially among younger patients, further research is essential to determine their safety and efficacy in various populations, including pediatric, geriatric, and those with comorbidities. Biologics and small molecules are improving AD treatment, as shown in this review.
- || Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Review, Journal, HEOR: Clinical and economic evaluation of tralokinumab for atopic dermatitis. (Pubmed Central) - Jul 1, 2024
This review was prepared by the University of Connecticut School of Pharmacy Academy of Managed Care Pharmacy (AMCP) Student Chapter. The student author group won the AMCP National Pharmacy and Therapeutics competition for their tralokinumab product review in March 2023.
- | Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca, Dupixent (dupilumab) / Sanofi, Regeneron
Journal, Real-world evidence, Real-world: Effectiveness of dupilumab in tralokinumab-resistant patients with atopic dermatitis: A real-world experience from two referral centres. (Pubmed Central) - Jun 28, 2024
The student author group won the AMCP National Pharmacy and Therapeutics competition for their tralokinumab product review in March 2023. No abstract available
- | Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Journal: First Short-Term Effectiveness and Security Data of Tralokinumab in Severe Atopic Dermatitis in Real Clinical Practice. (Pubmed Central) - Jun 25, 2024
No abstract available No abstract available
- || Review, Journal: Interleukin antagonists for atopic dermatitis: a new era of therapy. (Pubmed Central) - Jun 23, 2024
To date, the IL-4Ra-inhibitor dupilumab and the IL-13 inhibitor tralokinumab have gained regulatory approval in Europe for the treatment of moderate-to-severe AD, while more than 70 new therapeutics are currently in development...There is still an unmet need for real-world-evidence studies and head-to-head studies for both currently available and future agents in AD treatment. Establishing predictive biomarkers of treatment response in a disorder of such considerable heterogenicity might help physicians pursue a patient-tailored therapeutic response.
- |||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Enrollment open, Combination therapy: TRAPEDS 2: A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis (clinicaltrials.gov) - Jun 16, 2024
P3, N=195, Recruiting, Sponsor: LEO Pharma
Establishing predictive biomarkers of treatment response in a disorder of such considerable heterogenicity might help physicians pursue a patient-tailored therapeutic response. Not yet recruiting --> Recruiting
- | Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Journal: Tralokinumab-related facial redness: a therapeutic challenge. (Pubmed Central) - Jun 6, 2024
Not yet recruiting --> Recruiting No abstract available
- || Clinical, Review, Journal: Effectiveness and safety of systemic therapy for moderate-to-severe atopic dermatitis in children and adolescent patients: a systematic review. (Pubmed Central) - May 30, 2024
Awareness of adverse events and concomitant medications is crucial, and appropriate dosing and frequent laboratory and clinical monitoring are also essential. More real-world evidence and prospective cohort studies analyzing the effectiveness and safety of systemic therapies in children and adolescents are of paramount importance for optimizing personalized, effective, and safe management of the growing population of patients with atopic dermatitis in this age group.
- Dupixent (dupilumab) / Sanofi, Regeneron
Investigation of the inflammatory profile in tears of severe atopic dermatitis patients treated with dupilumab. A study of the BIOBADALER consortium (Poster Zone) - May 25, 2024 - Abstract #EAACI2024EAACI_2784;
This proportion is significantly higher than in severity-matched AD individuals or subjects receiving DU for asthma. The inflammatory profile in tears of AD-DU patients suggests the involvement of cytotoxic cells, natural killer cells or neutrophils in DU-induced conjunctivitis.
- ||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Enrollment change, Trial completion date, Trial primary completion date, Monotherapy: Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1) (clinicaltrials.gov) - May 15, 2024
P2, N=24, Active, not recruiting, Sponsor: LEO Pharma
The inflammatory profile in tears of AD-DU patients suggests the involvement of cytotoxic cells, natural killer cells or neutrophils in DU-induced conjunctivitis. N=53 --> 24 | Trial completion date: Sep 2025 --> Apr 2026 | Trial primary completion date: Aug 2024 --> Sep 2023
- | Journal: Italian S3-Guideline on the treatment of Atopic Eczema - Part 1: Systemic therapy, adapted from EuroGuiDerm by the Italian Society of Dermatology and STD (SIDEMAST), the Italian Association of Hospital Dermatologists (ADOI) and the Italian Society of Allergological and Environmental Dermatology (SIDAPA). (Pubmed Central) - May 10, 2024
The systemic treatment options discussed in the guideline comprise conventional immunosuppressive drugs (azathioprine, ciclosporin, glucocorticosteroids, methotrexate and mycophenolate mofetil), biologics (dupilumab, lebrikizumab, nemolizumab, omalizumab and tralokinumab) and janus kinase inhibitors (abrocitinib, baricitinib and upadacitinib). Part two of the guideline will address avoidance of provocation factors, dietary interventions, immunotherapy, complementary medicine, educational interventions, occupational and psychodermatological aspects, patient perspective and considerations for pediatric, adolescent, pregnant and breastfeeding patients.
- || Review, Journal: Comparison of Old and New Systemic Treatments for Moderate to Severe Atopic Dermatitis. (Pubmed Central) - May 7, 2024
High-dose upadacitinib was shown in another meta-analysis to be most effective in the measured outcomes but had the highest frequency of adverse events...Treatment can be individualized based on potency, adverse side effects, mechanism of action, and administration preference. Ongoing research continues to expand treatment options for AD.
- | Journal: Revolutionizing the management of patients with atopic dermatitis: practical considerations. (Pubmed Central) - Apr 29, 2024
Ongoing research continues to expand treatment options for AD. No abstract available
- Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca, Dupixent (dupilumab) / Sanofi, Regeneron
Acute onset of psoriasis during treatment with dupilumab and tralokinumab in patients with atopic dermatitis: real-life experience from a tertiary center (e-Poster Hall) - Apr 28, 2024 - Abstract #EADVSp2024EADV_Sp_163;
- || Biomarker, Review, Journal: Precision Dermatology: A Review of Molecular Biomarkers and Personalized Therapies. (Pubmed Central) - Apr 26, 2024
In HS, TNF-?, IL-1?, and MMPs serve as biomarkers, influencing targeted therapies like adalimumab and anakinra...AD biomarkers include ECP, IL-4, IL-13, guiding therapies like dupilumab and tralokinumab...CSU biomarkers encompass IgE, cytokines, and autologous serum tests, influencing therapies like omalizumab and cyclosporine...Precision medicine, driven by biomarkers, has shown success in skin malignancies. Future directions involve AI-powered algorithms, nanotechnology, and multi-omics integration for personalized dermatological care.
- || Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Review, Journal: Peripheral ulcerative keratitis associated with tralokinumab therapy: a case report and review of IL-13 inhibitor-associated ocular surface disease. (Pubmed Central) - Apr 16, 2024
This case report documents ulcerative keratitis occurring in association with tralokinumab therapy for AD, which has previously been described with dupilumab but not tralokinumab. This report demonstrates the need for vigilant ocular surface monitoring for patients on tralokinumab and illustrates successful management and long-term control of adverse ocular events associated with this medication.
- | New P4 trial, Predictive model: DermAtOmics-II: Optimization of Atopic Dermatitis Treatment That Requires Second-line Systemic Therapy Through Predictive Models (clinicaltrials.gov) - Apr 16, 2024
P4, N=150, Recruiting, Sponsor: Instituto de Investigaci
- | Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca, Dupixent (dupilumab) / Sanofi, Regeneron
Journal: Matching-Adjusted Indirect Comparison of the Efficacy at Week (Pubmed Central) - Apr 13, 2024
This report demonstrates the need for vigilant ocular surface monitoring for patients on tralokinumab and illustrates successful management and long-term control of adverse ocular events associated with this medication. The results of this analysis demonstrate that, in combination with TCS, tralokinumab and dupilumab have similar efficacy in the treatment of moderate-to-severe AD at 32
- Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Adbry, a targeted IL-13 inhibitor for moderate-to-severe atopic dermatitis (Theater 3, Expo Hall) - Apr 9, 2024 - Abstract #AMCP2024AMCP_539;
The results of this analysis demonstrate that, in combination with TCS, tralokinumab and dupilumab have similar efficacy in the treatment of moderate-to-severe AD at 32 Sponsored by LEO Pharma.
- | Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Journal: Efficacy and safety of tralokinumab in the treatment of head and neck pattern atopic dermatitis: A multicentre study of 12 patients. (Pubmed Central) - Apr 8, 2024
Sponsored by LEO Pharma. In real clinical practice, tralokinumab is demonstrated to be an effective and safe treatment for patients with AD and H&N pattern at short term.
- || Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca, Dupixent (dupilumab) / Sanofi, Regeneron
Review, Journal: Microbiome modulators for atopic eczema: a systematic review of experimental and investigational therapeutics. (Pubmed Central) - Apr 8, 2024
Topical probiotics reduce S. aureus abundance in AD lesional skin, yet for moderate-severe disease, these therapies may not reduce AD severity scores to the standard of biologics. Dupilumab and tralokinumab target key inflammatory pathways in AD and modulate the skin microbiome, further improving disease severity.
- Dupixent (dupilumab) / Sanofi, Regeneron
Investigation of the inflammatory profile in tears of severe atopic dermatitis patients treated with dupilumab. A study of the BIOBADALER consortium (Granada) - Apr 5, 2024 - Abstract #EAACI2024EAACI_787;
This proportion is significantly higher than in severity-matched AD individuals or subjects receiving DU for asthma. The inflammatory profile in tears of AD-DU patients suggests the involvement of cytotoxic cells, natural killer cells or neutrophils in DU-induced conjunctivitis.
- | Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Journal: Tralokinumab for the Treatment of Atopic Dermatitis in a Patient with Multiple Sclerosis. (Pubmed Central) - Apr 4, 2024
The inflammatory profile in tears of AD-DU patients suggests the involvement of cytotoxic cells, natural killer cells or neutrophils in DU-induced conjunctivitis. No abstract available
- | Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Journal: Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2?years. (Pubmed Central) - Apr 2, 2024
P3
No abstract available Tralokinumab treatment improved epidermal pathology, reduced systemic markers of type 2 inflammation, and shifted expression of key AD biomarkers in skin towards non-lesional levels, further highlighting the key role of IL-13 in the pathogenesis of AD.
- || Retrospective data, Review, Journal: Systematic review and network meta-analysis of the risk of Herpes zoster with biological therapies and selective Janus kinase-1 inhibitors in atopic dermatitis. (Pubmed Central) - Mar 27, 2024
JAK-1 inhibitors are associated with a significantly higher incidence of HZ compared to dupilumab and placebo. Our results suggest that recombinant HZ vaccination should be highly considered for all adult patients prior to starting oral JAK-1 inhibitors.
- |||||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
New P3 trial, Combination therapy: TRAPEDS 2: A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis (clinicaltrials.gov) - Mar 15, 2024
P3, N=195, Not yet recruiting, Sponsor: LEO Pharma